Growth Hormone Secretory Capacity Is Associated with Cardiac Morphology and Function in Overweight and Obese Patients: A Controlled, Cross-Sectional Study

Cells. 2022 Aug 4;11(15):2420. doi: 10.3390/cells11152420.

Abstract

Obesity is associated with increased cardiovascular morbidity. Adult patients with growth hormone deficiency (GHD) show morpho-functional cardiological alterations. A total of 353 overweight/obese patients are enrolled in the period between 2009 and 2019 to assess the relationships between GH secretory capacity and the metabolic phenotype, cardiovascular risk factors, body composition and cardiac echocardiographic parameters. All patients underwent GHRH + arginine test to evaluate GH secretory capacity, DEXA for body composition assessment and transthoracic echocardiography. Blood samples are also collected for the evaluation of metabolic parameters. In total, 144 patients had GH deficiency and 209 patients had normal GH secretion. In comparing the two groups, we found significant differences in body fat distribution with predominantly visceral adipose tissue accumulation in GHD patients. Metabolic syndrome is more prevalent in the GHD group. In particular, fasting glycemia, triglycerides and systolic and diastolic blood pressure are found to be linearly correlated with GH secretory capacity. Epicardial fat thickness, E/A ratio and indexed ventricular mass are worse in the GHD group. In the population studied, metabolic phenotype, body composition, cardiovascular risk factors and cardiac morphology are found to be related to the GH secretory capacity. GH secretion in the obese patient seems to be an important determinant of metabolic health.

Keywords: cardiovascular risk; echocardiography; epicardial fat; growth hormone; growth hormone deficiency; heart; metabolic syndrome; obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Body Composition
  • Cross-Sectional Studies
  • Human Growth Hormone* / metabolism
  • Humans
  • Obesity / metabolism
  • Overweight*

Substances

  • Human Growth Hormone

Grants and funding

This research was funded by the Italian Ministry of Education, University and Research PRIN 2017 and PRIN 2020, grants numbers 2017RS5M44_002, 2017L8Z2EM_005 and 2020NCKXBR_002. The funders had no role in the study design; decision to publish; or preparation of the manuscript.